Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : SK Chemicals
Deal Size : Inapplicable
Deal Type : Inapplicable
Standigm and SK Chemicals Repurpose FDA-Approved Drug into Rheumatoid Arthritis Candidate
Details : The compound in the patent was discovered by Standigm Insight™. In a mouse model, it showed comparable or better improvements in its rheumatoid arthritis disease activity score than reference drugs such as methotrexate and hydroxychloroquine.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : SK Chemicals
Deal Size : Inapplicable
Deal Type : Inapplicable